Navigation Links
Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Joint Status Conference in Federal Litigations
Date:3/30/2013

New York, New York (PRWEB) March 30, 2013

As women in the U.S. continue to file transvaginal mesh lawsuits, Bernstein Liebhard LLP reports that the next status conference in the federal litigations underway in the U.S. District Court for the Southern District of West Virginia will be held on April 18th at 1:00 p.m. According to a calendar posted on the court’s website, this joint Status Conference will take place in four federal transvaginal mesh litigations: In re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation (“MDL No. 2325”); In re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation (“MDL No. 2326); In re: C.R. Bard, Inc., Pelvic Repair Systems Products Liability Litigation (“MDL No. 2187”); and In re: Ethicon, Inc., Pelvic Repair Systems Products Liability Litigation (“ MDL No. 2327”). Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committees in all of these proceedings.

“We continue to hear from women who experienced the dangerous side effects of vaginal mesh. We are pleased to see these litigations moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm has filed transvaginal mesh lawsuits on behalf of hundreds of women who suffered pain, scarring, mesh erosion, infection and other side effects stemming from the surgical material. Claims pending in the four federal litigations of transvaginal mesh lawsuits were filed over products marketed by American Medical Systems, Inc., C.R. Bard, Inc., Ethicon, Inc. and Boston Scientific Corp.

Transvaginal Mesh Lawsuits
The number of lawsuits filed in the nationwide litigation surrounding transvaginal mesh has steadily increased since 2011, when the U.S. Food and Drug Administration (FDA) issued a public health alert stating there had been a five-fold increase in the amount of adverse event reports of transvaginal mesh complications filed with the agency. In the warning, the FDA also re-classified the frequency of vaginal mesh injuries stemming from pelvic organ prolapse repair as “not rare,” which was upgraded from its previous position that frequency of such complications was “rare.”*
Consolidated proceedings for transvaginal mesh lawsuits filed over products manufactured by Johnson & Johnson’s Ethicon unit and C.R. Bard are underway in New Jersey Superior Court, Atlantic County as well. (In re: Pelvic Mesh Litigation/Bard, No. L-6339-10, and In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10).
In both of these litigations, Bernstein Liebhard LLP partner, Jeffrey S. Grand is serving as Co-Liaison Counsel. Earlier this month, a jury in New Jersey Superior Court awarded more than $11 million to the Plaintiff in the nation’s first trial involving an Ethicon mesh product. As part of this reward, Johnson & Johnson was ordered to pay the Plaintiff $7.76 million in punitive damages. Mr. Grand was a member of the trial team. (Gross v. Gynecare Inc., Atl-L-6966-10, Superior Court of Atlantic County, New Jersey (Atlantic City))

Women who allegedly suffered transvaginal mesh complications after being implanted with the surgical material may be entitled to compensation for medical expenses, pain and suffering, and other damages incurred by their injuries. A wealth of transvaginal mesh lawsuit information can be found at Bernstein Liebhard's website. Please call 1-877-779-1414 to learn more.

*fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.ht

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
# # #

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.mesh-lawyers.net/

Read the full story at http://www.prweb.com/releases/tranvaginal-mesh-lawsuit/vaginal-mesh-complication/prweb10578668.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Transvaginal Mesh Lawyer Applauds PBS Program Questioning FDA’s Approval of Pelvic Mesh Products
2. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conferences in Federal Transvaginal Mesh Litigations
3. Vaginal Mesh Side Effect Sufferer Wins $3.35 Million Lawsuit; Transvaginal Mesh Attorney Jeff Nadrich Responds
4. US Drug Watchdog Now Urges Trial Law Firms To Join Them In A Effort To Help The Most Severely Injured Victims Of A Transvaginal Mesh Failure-With A Local Approach
5. US Drug Watchdog Now Urges Personal Injury Law Firms To Help Them Help Injured Individuals Of A Transvaginal Mesh Failure With A State Specific Approach-The Worst Victims
6. US Drug Watchdog Now Urges Top Personal Injury Trial Lawyers To Join Their State Specific Effort To Help Victims Of A Severe Transvaginal Mesh Failure To Get Compensation
7. US Drug Watchdog Now Invites Top Personal Injury Law Firms To Join Them In A State Specific Effort To Identify And Help Victims Of A Severe Transvaginal Mesh Failure
8. US Drug Watchdog Now Urges AV Rated Law Firms To Help Them Help More Victims Of A Severe Transvaginal Mesh Failure With A State Specific Approach
9. $3.35 Million Awarded in First Transvaginal Mesh Trial Verdict: Prompts McDonaldWorley.com Support Expansion
10. US Drug Watchdog Now Urges Trial Law Firms To Join Them In Their Effort To Help Severely Injured Victims Of A Transvaginal Mesh Failure-With A State Specific Approach
11. US Drug Watchdog Now Urges Victims Of A Transvaginal Mesh Failure To Call Them For The Names And Contacts Of Women Attorneys Who Also Have A Medical Background
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: